m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00326)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MGMT
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | mouse embryonic stem cells | Mus musculus |
Treatment: METTL3-/- ESCs
Control: Wild type ESCs
|
GSE145309 | |
Regulation |
|
logFC: -1.79E+00 p-value: 2.16E-20 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between MGMT and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 5.15E+00 | GSE60213 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Two critical DNA repair genes (Methylated-DNA--protein-cysteine methyltransferase (MGMT) and APNG) were m6A-modified by METTL3, whereas inhibited by METTL3 silencing or DAA-mediated total methylation inhibition, which is crucial for METTL3-improved temozolomide resistance in glioblastoma cells. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Glioblastoma | ICD-11: 2A00.00 | ||
Responsed Drug | Temozolomide | Approved | ||
Pathway Response | Nucleotide excision repair | hsa03420 | ||
Cell Process | DNA repair | |||
In-vitro Model | U251 (Fibroblasts or fibroblast like cells) | |||
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
In-vivo Model | Subcutaneously injected shMETTL3 or shNC-expressing U87-MG-TMZ cells into BALB/c NOD mice. After confirmation of GBM implantation, mice were treated with TMZ (66 mg/kg/d, 5 d per week, for 3 cycles). | |||
Brain cancer [ICD-11: 2A00]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Two critical DNA repair genes (Methylated-DNA--protein-cysteine methyltransferase (MGMT) and APNG) were m6A-modified by METTL3, whereas inhibited by METTL3 silencing or DAA-mediated total methylation inhibition, which is crucial for METTL3-improved temozolomide resistance in glioblastoma cells. | |||
Responsed Disease | Glioblastoma [ICD-11: 2A00.00] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Drug | Temozolomide | Approved | ||
Pathway Response | Nucleotide excision repair | hsa03420 | ||
Cell Process | DNA repair | |||
In-vitro Model | U251 (Fibroblasts or fibroblast like cells) | |||
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
In-vivo Model | Subcutaneously injected shMETTL3 or shNC-expressing U87-MG-TMZ cells into BALB/c NOD mice. After confirmation of GBM implantation, mice were treated with TMZ (66 mg/kg/d, 5 d per week, for 3 cycles). | |||
Temozolomide
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | Two critical DNA repair genes (Methylated-DNA--protein-cysteine methyltransferase (MGMT) and APNG) were m6A-modified by METTL3, whereas inhibited by METTL3 silencing or DAA-mediated total methylation inhibition, which is crucial for METTL3-improved temozolomide resistance in glioblastoma cells. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Glioblastoma | ICD-11: 2A00.00 | ||
Pathway Response | Nucleotide excision repair | hsa03420 | ||
Cell Process | DNA repair | |||
In-vitro Model | U251 (Fibroblasts or fibroblast like cells) | |||
U-87MG ATCC | Glioblastoma | Homo sapiens | CVCL_0022 | |
In-vivo Model | Subcutaneously injected shMETTL3 or shNC-expressing U87-MG-TMZ cells into BALB/c NOD mice. After confirmation of GBM implantation, mice were treated with TMZ (66 mg/kg/d, 5 d per week, for 3 cycles). | |||